{
  "docId": "019dd923-5e88-73ef-bd5d-0856e1444fb9",
  "docSlug": "8757f1b44ef7f176",
  "documentTitle": "2024 Air Street Capital The State of AI Report 2024",
  "authorId": "AirStreetCapital",
  "authorName": "Air Street Capital",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "vc_research",
  "sourceTypeLabel": "VC research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.777,
  "pageNumber": 145,
  "pageCount": 213,
  "prevPage": 144,
  "nextPage": 146,
  "slideType": "industry_trends",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "The slide summarizes clinical progress in personalized cancer vaccines, highlighting specific patient outcomes and trial data.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "bullet_list",
    "logo_grid"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5d-0856e1444fb9/145",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5d-0856e1444fb9",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5d-0856e1444fb9.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5d-0856e1444fb9#slide-145",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "New positive data shows that INTs are having promising therapeutic effects in aggressive melanoma (skin) and pancreatic cancer.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-47c3-7407-8d1d-02f5fd38479b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.9,
        "x": 0.05,
        "y": 0.48
      },
      "kind": "list",
      "text": "In April 2024, BioNTech shared 3-year follow-up data from a Phase 1 trial with their BNT122 (INT) in pancreatic cancer. 8 of 16 patients saw high-magnitude T cells specific to the encoded neoantigens.\n6 of these 8 patients remained disease-free during the 3-year follow-up period. Of the 8 patients who didn’t see an immune response, 7 showed tumor recurrence.\nIn June 2024, Moderna and Merck announced 3-year Phase 2b trial (n=157 patients) data showing that mRNA-4157 (V940, INT) in combination with KEYTRUDA (melanoma drug) reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% vs. KEYTRUDA alone in melanoma patients.\nThe 2.5-year recurrence-free survival rate of mRNA-4157 (V940) in combination with KEYTRUDA was 74.8% as compared to 55.6% for KEYTRUDA alone.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3243e97e-7125-45fa-82bd-aca77420fc91",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "recurrence-free survival rate: 74.8%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-47c3-7407-8d1d-05d859866bca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "Covid darlings Moderna and BioNTech are generating individualised “neoantigen” therapies (INT) to fight cancer. INTs are composed of mRNAs that encode predicted neoantigens, cancer-specific mutations that act as antigens generated by tumor cells. These “neoantigens” prompt the patient’s immune system to clear the tumor cells that produce them. New positive data shows that INTs are having promising therapeutic effects in aggressive melanoma (skin) and pancreatic cancer. INTs present significant manufacturing and logistics issues.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b36b7b99-0aed-4c21-8cd8-16cfd0b690b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.14
      },
      "kind": "title",
      "text": "Personalising cancer therapy with mRNA vaccines and predicted neoantigens",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee8e0e49-c7ec-427d-873e-790a8ec58a8e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 153,
      "from": 9,
      "beatId": "019dd95a-0682-776c-8e35-5f2398b8d1d0",
      "arcName": "The Triple Take",
      "arcSlug": "triple-take",
      "beatName": "The Facts (What)",
      "beatSlug": "triple-take-the-facts-what",
      "evidence": "Exec summary + Research + Industry sections inventory the year",
      "position": 1,
      "confidence": 78,
      "parentBeatName": "Setup",
      "parentBeatSlug": "setup"
    },
    {
      "to": 174,
      "from": 86,
      "beatId": "019dd95a-0682-776c-8e35-73133c63a096",
      "arcName": "Voyage and Return",
      "arcSlug": "voyage-return",
      "beatName": "Discoveries",
      "beatSlug": "voyage-return-discoveries",
      "evidence": "Industry + Politics findings on NVIDIA, regulation, geopolitics",
      "position": 3,
      "confidence": 55,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 147,
      "from": 137,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "019dd95a-07fe-70ce-8d3e-5d103aecde20",
      "evidence": "Law 90%, Apple+OpenAI, Unsloth, Recursion-Exscientia, video gen race, Kling, mRNA, Ray-Ban, Rabbit R1",
      "position": 16,
      "objective": "Show AI penetration into law/medicine/devices/glasses verticals",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 65,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}